Drug Profile
Elinzanetant - Bayer
Alternative Names: BAY-3427080; GSK-1144814; NT 814Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Bayer; GlaxoSmithKline; NeRRe Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Antipsychotics; Drug withdrawal therapies; Fluorobenzenes; Oxazines; Piperazines; Pyridines; Small molecules
- Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Vasomotor symptoms
- Phase II Sex hormone disorders; Sleep disorders
- Discontinued Opioid-related disorders; Schizophrenia
Most Recent Events
- 19 Mar 2024 Efficacy and adverse events data from phase-III OASIS-3 trial in Vasomotor symptoms released by Bayer
- 12 Feb 2024 Bayer completes a Phase-III OASIS-3 clinical trial in Vasomotor symptoms (In the elderly, In adults) in Spain, Poland, Finland, Denmark, Canada, Belgium, Bulgaria, United Kingdom (PO) (NCT05030584)
- 08 Jan 2024 Bayer initiates phase I trial in Vasomotor symptoms (In adults, In the elderly) in Canada (PO) (NCT06219902)